11 November 2020
Quebec-based Medicago announced positive interim results from the Phase I clinical trial of its plant-derived Covid-19 vaccine candidate. The results showed that that 100% of the subjects developed significant antibody and cellular immune responses after being administered two doses of Medicago’s adjuvanted vaccine candidate.
Go deeper with GlobalData
Intas has launched Thymotas, a patented formulation of Thymoquinone that shows efficacy in fighting the SAR-CoV-2 infection. An active biological component of black cumin, Thymotas is clinically tested to be an add-on to the current standard of care for Covid-19. Various research has supported its beneficial properties, but it has been developed as a tablet for the first time by Intas.
The Medigen Vaccine Biologics Corporation and BlueWillow Biologics have collaborated to develop the S-2P-NE-01, a nasal vaccine targeting the SARS-CoV-2 virus. BlueWillow manufactures intranasal vaccines with its patented NanoVax adjuvant. Research shows that intranasal administration stimulates mucosal immunity.
Atossa Therapeutics announced positive results of its proprietary nasal spray candidate, AT-301, in its Phase I clinical study. The drug was found to be both tolerable and safe in this study when administered in single and multiple dose forms over a period of 14 days. AT-301 is being developed for recently diagnosed Covid-19 patients for at home use.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
